000142871 001__ 142871
000142871 005__ 20240229112532.0
000142871 0247_ $$2doi$$a10.1136/gutjnl-2017-314828
000142871 0247_ $$2pmid$$apmid:29158237
000142871 0247_ $$2ISSN$$a0017-5749
000142871 0247_ $$2ISSN$$a1468-3288
000142871 0247_ $$2altmetric$$aaltmetric:29388632
000142871 037__ $$aDKFZ-2019-00501
000142871 041__ $$aeng
000142871 082__ $$a610
000142871 1001_ $$0P:(DE-He78)448ff49e51672d79b4747339ac15c898$$aHuang, Lei$$b0$$eFirst author$$udkfz
000142871 245__ $$aResection of pancreatic cancer in Europe and USA: an international large-scale study highlighting large variations.
000142871 260__ $$aLondon$$bBMJ Publishing Group$$c2019
000142871 3367_ $$2DRIVER$$aarticle
000142871 3367_ $$2DataCite$$aOutput Types/Journal article
000142871 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1661347255_8349
000142871 3367_ $$2BibTeX$$aARTICLE
000142871 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000142871 3367_ $$00$$2EndNote$$aJournal Article
000142871 520__ $$aResection can potentially cure resectable pancreatic cancer (PaC) and significantly prolong survival in some patients. This large-scale international study aimed to investigate variations in resection for PaC in Europe and USA and determinants for its utilisation.Data from six European population-based cancer registries and the US Surveillance, Epidemiology, and End Results Program database during 2003-2016 were analysed. Age-standardised resection rates for overall and stage I-II PaCs were computed. Associations between resection and demographic and clinical parameters were assessed using multivariable logistic regression models.A total of 153 698 records were analysed. In population-based registries in 2012-2014, resection rates ranged from 13.2% (Estonia) to 21.2% (Slovenia) overall and from 34.8% (Norway) to 68.7% (Denmark) for stage I-II tumours, with great international variations. During 2003-2014, resection rates only increased in USA, the Netherlands and Denmark. Resection was significantly less frequently performed with more advanced tumour stage (ORs for stage III and IV versus stage I-II tumours: 0.05-0.18 and 0.01-0.06 across countries) and increasing age (ORs for patients 70-79 and ≥80 versus those <60 years: 0.37-0.63 and 0.03-0.16 across countries). Patients with advanced-stage tumours (stage III-IV: 63.8%-81.2%) and at older ages (≥70 years: 52.6%-59.5%) receiving less frequently resection comprised the majority of diagnosed cases. Patient performance status, tumour location and size were also associated with resection application.Rates of PaC resection remain low in Europe and USA with great international variations. Further studies are warranted to explore reasons for these variations.
000142871 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000142871 588__ $$aDataset connected to CrossRef, PubMed,
000142871 7001_ $$0P:(DE-He78)bbfe0ebad1e3b608bca2b49d4f86bd09$$aJansen, Lina$$b1$$udkfz
000142871 7001_ $$0P:(DE-He78)48988e4552476bf82978f0e1ac8a4cf0$$aBalavarca, Yesilda$$b2$$udkfz
000142871 7001_ $$aMolina-Montes, Esther$$b3
000142871 7001_ $$0P:(DE-He78)b16bd486ec798cca3184e838e7f49ac4$$aBabaei, Masoud$$b4$$udkfz
000142871 7001_ $$avan der Geest, Lydia$$b5
000142871 7001_ $$aLemmens, Valery$$b6
000142871 7001_ $$aVan Eycken, Liesbet$$b7
000142871 7001_ $$aDe Schutter, Harlinde$$b8
000142871 7001_ $$aJohannesen, Tom B$$b9
000142871 7001_ $$aFristrup, Claus W$$b10
000142871 7001_ $$aMortensen, Michael B$$b11
000142871 7001_ $$aPrimic-Žakelj, Maja$$b12
000142871 7001_ $$aZadnik, Vesna$$b13
000142871 7001_ $$0P:(DE-He78)1573258b58c33f1922ca9719d0c8c4ab$$aBecker, Nikolaus$$b14$$udkfz
000142871 7001_ $$aHackert, Thilo$$b15
000142871 7001_ $$aMägi, Margit$$b16
000142871 7001_ $$aCassetti, Tiziana$$b17
000142871 7001_ $$aSassatelli, Romano$$b18
000142871 7001_ $$aGrützmann, Robert$$b19
000142871 7001_ $$aMerkel, Susanne$$b20
000142871 7001_ $$aGonçalves, Ana F$$b21
000142871 7001_ $$aBento, Maria J$$b22
000142871 7001_ $$aHegyi, Péter$$b23
000142871 7001_ $$aLakatos, Gábor$$b24
000142871 7001_ $$aSzentesi, Andrea$$b25
000142871 7001_ $$aMoreau, Michel$$b26
000142871 7001_ $$avan de Velde, Tony$$b27
000142871 7001_ $$aBroeks, Annegien$$b28
000142871 7001_ $$aSant, Milena$$b29
000142871 7001_ $$aMinicozzi, Pamela$$b30
000142871 7001_ $$aMazzaferro, Vincenzo$$b31
000142871 7001_ $$aReal, Francisco X$$b32
000142871 7001_ $$aCarrato, Alfredo$$b33
000142871 7001_ $$aMolero, Xavier$$b34
000142871 7001_ $$aBesselink, Marc G$$b35
000142871 7001_ $$aMalats, Núria$$b36
000142871 7001_ $$aBüchler, Markus W$$b37
000142871 7001_ $$0P:(DE-He78)01ef71f71b01a3ec3b698653fd43fe86$$aSchrotz-King, Petra$$b38$$udkfz
000142871 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b39$$eLast author$$udkfz
000142871 773__ $$0PERI:(DE-600)1492637-4$$a10.1136/gutjnl-2017-314828$$gVol. 68, no. 1, p. 130 - 139$$n1$$p130 - 139$$tGut$$v68$$x1468-3288$$y2019
000142871 909CO $$ooai:inrepo02.dkfz.de:142871$$pVDB
000142871 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)448ff49e51672d79b4747339ac15c898$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000142871 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)bbfe0ebad1e3b608bca2b49d4f86bd09$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000142871 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)48988e4552476bf82978f0e1ac8a4cf0$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000142871 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)b16bd486ec798cca3184e838e7f49ac4$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000142871 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)1573258b58c33f1922ca9719d0c8c4ab$$aDeutsches Krebsforschungszentrum$$b14$$kDKFZ
000142871 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)01ef71f71b01a3ec3b698653fd43fe86$$aDeutsches Krebsforschungszentrum$$b38$$kDKFZ
000142871 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b39$$kDKFZ
000142871 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000142871 9141_ $$y2019
000142871 915__ $$0StatID:(DE-HGF)0410$$2StatID$$aAllianz-Lizenz
000142871 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000142871 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bGUT : 2017
000142871 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000142871 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000142871 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000142871 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central
000142871 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000142871 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000142871 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000142871 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000142871 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000142871 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000142871 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000142871 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000142871 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000142871 915__ $$0StatID:(DE-HGF)9915$$2StatID$$aIF >= 15$$bGUT : 2017
000142871 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000142871 9201_ $$0I:(DE-He78)C120-20160331$$kC120$$lPräventive Onkologie$$x1
000142871 9201_ $$0I:(DE-He78)L101-20160331$$kL101$$lDKTK Heidelberg$$x2
000142871 980__ $$ajournal
000142871 980__ $$aVDB
000142871 980__ $$aI:(DE-He78)C070-20160331
000142871 980__ $$aI:(DE-He78)C120-20160331
000142871 980__ $$aI:(DE-He78)L101-20160331
000142871 980__ $$aUNRESTRICTED